Lymphokine-activated killer cell (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lymphokine-activated killer cell" in English language version.

refsWebsite

Global rank English rank

13nih.gov

4^th place

7doi.org

2^nd place

1worldcat.org

5^th place

doi.org

Grimm, E. A.; Mazumder, A.; Zhang, H. Z.; Rosenberg, S. A. (1982-06-01). "Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes". The Journal of Experimental Medicine. 155 (6): 1823–1841. doi:10.1084/jem.155.6.1823. ISSN 0022-1007. PMC 2186695. PMID 6176669.
West EJ, Scott KJ, Jennings VA, Melcher AA (September 2011). "Immune activation by combination human lymphokine-activated killer and dendritic cell therapy". Br J Cancer. 105 (6): 787–95. doi:10.1038/bjc.2011.290. PMC 3171008. PMID 21847125.
Rosenberg SA (June 2014). "IL-2: the first effective immunotherapy for human cancer". J Immunol. 192 (12): 5451–8. doi:10.4049/jimmunol.1490019. PMC 6293462. PMID 24907378.
Maeta N, Tamura K, Takemitsu H, Miyabe M (July 2019). "Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats". Open Vet J. 9 (2): 147–150. doi:10.4314/ovj.v9i2.9. PMC 6626148. PMID 31360654.
Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA (March 2014). "Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites". Int J Cancer. 134 (5): 1091–101. doi:10.1002/ijc.28450. PMC 4321045. PMID 23982804.
Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B (November 2014). "Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1". Biochem Pharmacol. 92 (2): 312–25. doi:10.1016/j.bcp.2014.07.014. PMID 25069049.
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (October 1989). "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients". Ann Surg. 210 (4): 474–84, discussion 484–5. doi:10.1097/00000658-198910000-00008. PMC 1357927. PMID 2679456.

nih.gov

pubmed.ncbi.nlm.nih.gov

Grimm, E. A.; Mazumder, A.; Zhang, H. Z.; Rosenberg, S. A. (1982-06-01). "Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes". The Journal of Experimental Medicine. 155 (6): 1823–1841. doi:10.1084/jem.155.6.1823. ISSN 0022-1007. PMC 2186695. PMID 6176669.
West EJ, Scott KJ, Jennings VA, Melcher AA (September 2011). "Immune activation by combination human lymphokine-activated killer and dendritic cell therapy". Br J Cancer. 105 (6): 787–95. doi:10.1038/bjc.2011.290. PMC 3171008. PMID 21847125.
Rosenberg SA (June 2014). "IL-2: the first effective immunotherapy for human cancer". J Immunol. 192 (12): 5451–8. doi:10.4049/jimmunol.1490019. PMC 6293462. PMID 24907378.
Maeta N, Tamura K, Takemitsu H, Miyabe M (July 2019). "Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats". Open Vet J. 9 (2): 147–150. doi:10.4314/ovj.v9i2.9. PMC 6626148. PMID 31360654.
Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA (March 2014). "Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites". Int J Cancer. 134 (5): 1091–101. doi:10.1002/ijc.28450. PMC 4321045. PMID 23982804.
Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B (November 2014). "Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1". Biochem Pharmacol. 92 (2): 312–25. doi:10.1016/j.bcp.2014.07.014. PMID 25069049.
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (October 1989). "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients". Ann Surg. 210 (4): 474–84, discussion 484–5. doi:10.1097/00000658-198910000-00008. PMC 1357927. PMID 2679456.

ncbi.nlm.nih.gov

Grimm, E. A.; Mazumder, A.; Zhang, H. Z.; Rosenberg, S. A. (1982-06-01). "Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes". The Journal of Experimental Medicine. 155 (6): 1823–1841. doi:10.1084/jem.155.6.1823. ISSN 0022-1007. PMC 2186695. PMID 6176669.
West EJ, Scott KJ, Jennings VA, Melcher AA (September 2011). "Immune activation by combination human lymphokine-activated killer and dendritic cell therapy". Br J Cancer. 105 (6): 787–95. doi:10.1038/bjc.2011.290. PMC 3171008. PMID 21847125.
Rosenberg SA (June 2014). "IL-2: the first effective immunotherapy for human cancer". J Immunol. 192 (12): 5451–8. doi:10.4049/jimmunol.1490019. PMC 6293462. PMID 24907378.
Maeta N, Tamura K, Takemitsu H, Miyabe M (July 2019). "Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats". Open Vet J. 9 (2): 147–150. doi:10.4314/ovj.v9i2.9. PMC 6626148. PMID 31360654.
Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA (March 2014). "Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites". Int J Cancer. 134 (5): 1091–101. doi:10.1002/ijc.28450. PMC 4321045. PMID 23982804.
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (October 1989). "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients". Ann Surg. 210 (4): 474–84, discussion 484–5. doi:10.1097/00000658-198910000-00008. PMC 1357927. PMID 2679456.

worldcat.org

search.worldcat.org

Grimm, E. A.; Mazumder, A.; Zhang, H. Z.; Rosenberg, S. A. (1982-06-01). "Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes". The Journal of Experimental Medicine. 155 (6): 1823–1841. doi:10.1084/jem.155.6.1823. ISSN 0022-1007. PMC 2186695. PMID 6176669.